8:15 am Chair’s Opening Remarks

Updates on Clinical Development for Psychiatry

8:30 am Fireside Chat: What’s Coming Next in the Clinic?


An expert discussion on where the field of therapeutic development in psychiatry is headed and what the biggest roadblocks are to reaching the goal of effective treatment for all indications in mental health

8:45 am Progressing from Treatment Resistant Depression with Novel Impactful Therapeutics


  • Expanding on the role of alternative receptors and allosteric modulation in therapeutic options
  • Uncovering updates from research to predict drug response patterns
  • How can patients with depression be stratified to streamline treatment decisions?

9:15 am Acute Treatment of Social Anxiety Disorder: Emerging Regulatory Landscape Facilitates Pipeline Development


  • Reviewing current chronic and acute FDA-approved and off-label drug treatment for SAD
  • Emerging regulatory landscape has paved the path for rapid development of fast-acting medications for acute treatment of SAD without the liabilities of benzodiazepines
  • The pipeline of candidates in development for acute treatment of SAD will be reviewed

9:45 am Speed Networking


Grab a quick cup of tea or coffee and jump into the speed networking session. Don’t miss this fantastic opportunity to connect with new contacts from active companies involved in drug development for psychiatric disorders. Network and form lasting connections in this exclusive Speed Networking session.

10:15 am Morning Break & Networking

10:45 am Tackling the Opioid Overdose Crisis: Where Are We Now?


  • Examining the evolution of the opioid overdose crisis
  • Outlining innovative approaches to treat opioid overdose
  • Can the efficacy of rescue agents be evaluated in controlled clinical trials?

11:15 am Attending the Holistic Care of Schizophrenia: The Negative & The Positive

  • John Renger Chief Scientific Officer, Cerevel Therapeutics


  • Reviewing therapeutic development to cover negative symptoms of schizophrenia
  •  Examining novel mechanisms of action for antipsychotics to yield refined results
  •  Discussing the future potential within schizophrenia for symptom-centric treatment

11:45 am Expert Speaker Interactive Q&A

12:15 pm Lunch & Networking

Translating the Language of the Mind – From Models to Clinic

1:15 pm Avoiding Pitfalls in Clinical Trial Design & Execution in the Post-Big Pharma Era


  • Understanding up-to-date methodologies to identify
  • Capitalizing on insights from efficient and suboptimal designs
  • Exploring navigation of studies in the modern setting

1:45 pm A General Theory of Construct Enrichment: Inclusion Criteria for Symptom Structure not Just Severity

  • Seth Hopkins Executive Director Translational Science, Sunovion Pharmaceuticals


  • Exploring case studies from depression and schizophrenia indication registration trials
  • Optimizing the match between psychiatric scale, trial population, and endpoint to increase the validity and power of clinical trials

2:15 pm Highlighting the Integration of Machine Learning to Enhance Preclinical Drug Discovery

  • Zoe Hughes Vice President & Head of Biology, Gilgamesh Pharmaceuticals


  • Implementing machine learning based classification of animal behavior to guide drug development
  • Using quantitative biomarkers to refine translational data for the identification of lead molecules
  • Dissecting key examples to outline utility of novel AI discovery platform

2:45 pm Afternoon Break & Networking

3:30 pm The Hype & The Hope: Utilization of Model Behaviors to Accurately Predict Clinical Efficacy

  • Scott Thompson Professor & Chair Department of Physiology, University of Maryland


  • Examining the insufficiencies in current models for psychiatric drug development
  • Evaluating validation of models of anhedonic rodent behavior for application in pipelines
  • Exploring application of translational models in reviewing action of psychedelic therapeutics

4:00 pm Translational & Cross-Species Approaches to Anhedonia: Implications for Treatment Development & Stratification


  • Utilization of fMRI, EEG and PET in identification of neural substrates
  • Reviewing the importance of anhedonia as an endophenotype of depression
  •  Outlining the considerations to be made in therapeutics development for depression based on findings

4:30 pm Expert Speaker Interactive Q&A

  • Zoe Hughes Vice President & Head of Biology, Gilgamesh Pharmaceuticals
  • Scott Thompson Professor & Chair Department of Physiology, University of Maryland
  • Diego Pizzagalli Professor of Psychiatry, Harvard Medical School

5:00 pm End of Day Wrap-Up